These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Hennenlotter A; Schroeder U; Erhard P; Haslinger B; Stahl R; Weindl A; von Einsiedel HG; Lange KW; Ceballos-Baumann AO Brain; 2004 Jun; 127(Pt 6):1446-53. PubMed ID: 15090475 [TBL] [Abstract][Full Text] [Related]
6. Some ethical problems in Huntington's chorea. Perry TL Can Med Assoc J; 1981 Nov; 125(10):1098-100. PubMed ID: 6459840 [No Abstract] [Full Text] [Related]
7. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea]. Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360 [TBL] [Abstract][Full Text] [Related]
9. Trinucleotide repeat length instability and age of onset in Huntington's disease. Duyao M; Ambrose C; Myers R; Novelletto A; Persichetti F; Frontali M; Folstein S; Ross C; Franz M; Abbott M Nat Genet; 1993 Aug; 4(4):387-92. PubMed ID: 8401587 [TBL] [Abstract][Full Text] [Related]
10. A genetic study of red cell osmotic fragility in Huntington's disease. McCormack MK; Lazzarini A; Toke D; Lepore F Am J Med Genet; 1984 May; 18(1):5-11. PubMed ID: 6234801 [TBL] [Abstract][Full Text] [Related]
11. The relationship between CAG repeat length and clinical progression in Huntington's disease. Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767 [TBL] [Abstract][Full Text] [Related]
12. [Huntington's disease]. Heiberg A Tidsskr Nor Laegeforen; 2008 Oct; 128(19):2214-7. PubMed ID: 18846148 [TBL] [Abstract][Full Text] [Related]
14. Trinucleotide repeat length and rate of progression of Huntington's disease. Illarioshkin SN; Igarashi S; Onodera O; Markova ED; Nikolskaya NN; Tanaka H; Chabrashwili TZ; Insarova NG; Endo K; Ivanova-Smolenskaya IA Ann Neurol; 1994 Oct; 36(4):630-5. PubMed ID: 7944295 [TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges]. Bantubungi K; Blum D Rev Med Brux; 2007; 28(6):487-94. PubMed ID: 18265808 [TBL] [Abstract][Full Text] [Related]
16. Animal models of Huntington's disease. Gárdián G Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874 [TBL] [Abstract][Full Text] [Related]
17. Electromyographic silent period after transcranial brain stimulation in Huntington's disease. Priori A; Berardelli A; Inghilleri M; Polidori L; Manfredi M Mov Disord; 1994 Mar; 9(2):178-82. PubMed ID: 8196679 [TBL] [Abstract][Full Text] [Related]
18. Huntington's disease: genetics, chemical pathology, and management. Myers RH; Schoenfeld M; Bird ED Prog Med Genet; 1985; 6():91-122. PubMed ID: 2873625 [No Abstract] [Full Text] [Related]
19. ECT for the treatment of Huntington's disease: a case study. Beale MD; Kellner CH; Gurecki P; Pritchett JT Convuls Ther; 1997 Jun; 13(2):108-12. PubMed ID: 9253530 [TBL] [Abstract][Full Text] [Related]